换一批
换一批A comprehensive review on Brigatinib - A wonder drug for targeted cancer therapy in non-small cell lung cancer.
作者：
关键词
ALCL, anaplastic extensive cell lymphomaALK inhibitorsALK, anaplastic lymphoma kinaseALTA-1L, ALK in lung cancer trial of Brigatinib in1st LineBCRP, breast cancer resistance proteinBrigatinibDMPO, dimethyl phosphine oxideEGFR, epidermal growth factor receptorEML4, echinoderm microtubule associated proteinFDA, Food and Drug AdministrationFLT3, fem like tyrosine kinase-3KinaseLCC, Large Cell CarcinomaLung cancerLymphomaMIC, minimum inhibitory concentrationNPM, nucleophosminNSCLC, non-small cell lung cancerORR, objective response rateP-gp, P-glycoproteinSAR, structure activity relationshipTKI’s, tyrosine kinase inhibitors
DOI
10.1016/j.jsps.2018.04.010
PMID
30202213
发布时间
2023-09-28
- 浏览4
Saudi pharmaceutical journal
2018年26卷6期
755-763页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
